One of the major challenges in prostate cancer therapy remains the development of effective treatments for castration-resistant prostate cancer (CRPC), as the underlying mechanisms for its progression remain elusive. Previous studies showed that androgen receptor (AR) is crucially involved in regulation of metabolism in prostate cancer (PCa) cells throughout the transition from early stage, androgen-sensitive PCa to androgen-independent CRPC. AR achieves such metabolic rewiring directively either via its transcriptional activity or via interactions with AMP-activated protein kinase (AMPK). However, due to the heterogeneous expression and activity status of AR in PCa cells, it remains a challenge to investigate the links between AR status an...
The androgen receptor (AR) plays a central role in prostate, muscle, bone and adipose tissue. Moreov...
Abstract Prostate cancer is one of the most common malignancies in men and is predicted to be the se...
Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen rece...
One of the major challenges in prostate cancer therapy remains the development of effective treatmen...
Androgen signaling via the androgen receptor (AR) is involved in normal prostate development and pro...
Prostate cancer is the most commonly diagnosed malignancy among men in industrialized countries, acc...
Prostate cancer (PCa) is the second most common cancer affecting men worldwide. PCa shows a broad-sp...
Androgen-deprivation remains the principal therapy for advanced and metastatic prostate cancers. Ho...
Prostate cancer growth is driven by androgen signaling using the androgen receptor (AR). Androg...
The androgen receptor (AR) is a ligand-dependent transcription factor. Binding of androgens induces...
Prostate cancer (PCa) is the second leading cause of cancer-related death in the US. Androgen recept...
The androgen receptor (AR) is a key regulator of prostate growth and the principal drug target for t...
Prostate cancer (PCa) is the most frequently diagnosed male cancer in Australia and a leading cause ...
Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen rece...
Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen rece...
The androgen receptor (AR) plays a central role in prostate, muscle, bone and adipose tissue. Moreov...
Abstract Prostate cancer is one of the most common malignancies in men and is predicted to be the se...
Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen rece...
One of the major challenges in prostate cancer therapy remains the development of effective treatmen...
Androgen signaling via the androgen receptor (AR) is involved in normal prostate development and pro...
Prostate cancer is the most commonly diagnosed malignancy among men in industrialized countries, acc...
Prostate cancer (PCa) is the second most common cancer affecting men worldwide. PCa shows a broad-sp...
Androgen-deprivation remains the principal therapy for advanced and metastatic prostate cancers. Ho...
Prostate cancer growth is driven by androgen signaling using the androgen receptor (AR). Androg...
The androgen receptor (AR) is a ligand-dependent transcription factor. Binding of androgens induces...
Prostate cancer (PCa) is the second leading cause of cancer-related death in the US. Androgen recept...
The androgen receptor (AR) is a key regulator of prostate growth and the principal drug target for t...
Prostate cancer (PCa) is the most frequently diagnosed male cancer in Australia and a leading cause ...
Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen rece...
Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen rece...
The androgen receptor (AR) plays a central role in prostate, muscle, bone and adipose tissue. Moreov...
Abstract Prostate cancer is one of the most common malignancies in men and is predicted to be the se...
Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen rece...